Approved: 07.01.2015
Revised: 08.01.2020

Statens legemiddelverk

OTC use in Norway for noscapine, ATC-code: R05D A07

- This OTC substance report is based on the assessment of the OTC indication and posology for products containing noscapine. It defines the preferred Norwegian wording for the package leaflet and labelling for OTC products containing noscapine. In addition, an overview of the approvable strength(s), pharmaceutical form(s) and pack size(s) exempt from medical prescription in Norway is included.

- The proposed OTC indication and posology in the OTC package leaflet and labelling must be covered by the information approved in the corresponding SmPC.

Preparations for oral use, up to 50 mg or 2.2 mg/ml

1. Package leaflet

1.1 Indication

Hostedempende ved tørrhoste

1.2 Posology

Change the quantity from the given strength to the number of entities to be taken (e.g. 1–2 tablets, 1 suppository, 20 ml…). The text below include the posology and the necessary information included for the most commonly used pharmaceutical dose forms.

Solid formulations

Voksne og barn over 14 år: 50 mg 3 ganger daglig.

Barn 6–14 år: 25 mg 3 ganger daglig.

<Legemiddelform> <svelges hele og> tas minimum ½ time før eller 2 timer etter mat.

Liquid formulations

Voksne og barn over 14 år: 44 mg 3 ganger daglig.

Barn 10–14 år: 33 mg 3 ganger daglig.

Barn 6–10 år: 22 mg 3 ganger daglig.

Barn 2–6 år: 11 mg 3 ganger daglig.

Bruk måleredskap. Ta <legemiddelform> minimum ½ time før eller 2 timer etter mat.

2. Labelling

2.1 Indication

State the indication as in the PIL. If the full indication is stated on the back panel of the package, the following abbreviation can be used on the front panel:

Hostedempende ved tørrhoste

2.2 Posology

State the dosage as in the PIL.

2.3 Other information

Not applicable.

3. Content of the pack

The table below presents the highest level of the terms for approvable pharmaceutical forms, if possible. For example: the term "tablets" includes all types of tablet formulations as for example film coated tablets or chewable tablets. For active substances where some pharmaceutical forms are exempt from approval due to safety concern, this is stated explicitly below the table.

Pharmaceutical form	**Maximum strength**	**Maximum pack size**
Tablets, capsules, granules or powder in sachets	50 mg	50
Oral solutions	2.2 mg/ml	250 ml